The landscape of pharmaceutical compliance is undergoing significant transformation as industry leaders adapt to rapid regulatory changes and emerging technologies.
During a recent webinar hosted by the Pharmaceutical Compliance Congress, experts highlighted the mounting challenges compliance teams face in an evolving environment. Tim Stow, global head of ethics and compliance at Galderma, noted the dual pressures of adapting to new regulations while managing traditional compliance responsibilities. He emphasized that the compliance landscape is increasingly complex, requiring professionals to navigate these changes effectively.
Catherine Shimsky, vice president at Novartis, echoed Stow's sentiments, pointing out that the pace of change is intensifying. She remarked that compliance practitioners are tasked not only with implementing new policies but also with ensuring that their organizations maintain a sense of security and confidence in meeting compliance standards. The ability to balance stability with the necessity for transformation is becoming a critical focus for compliance teams as they move into 2026.
This evolving compliance landscape underscores the importance of agility in the pharmaceutical industry. As regulations and technologies continue to shift, organizations must prioritize adaptive strategies to ensure robust compliance frameworks that can withstand future challenges.